女性不妊症治療薬の世界市場2019-2023...市場調査レポートについてご紹介

PART 01: EXECUTIVE SUMMARY

PART 02: SCOPE OF THE REPORT

2.1 Preface

2.2 Preface

2.3 Currency conversion rates for US$

PART 03: MARKET LANDSCAPE

Market ecosystem

Market characteristics

Market segmentation analysis

PART 04: MARKET SIZING

Market definition

Market sizing 2018

Market size and forecast 2018-2023

PART 05: FIVE FORCES ANALYSIS

Bargaining power of buyers

Bargaining power of suppliers

Threat of new entrants

Threat of substitutes

Threat of rivalry

Market condition

PART 06: MARKET SEGMENTATION BY ROA

Market segmentation by RoA

Comparison by RoA

Parenteral – Market size and forecast 2018-2023

Oral – Market size and forecast 2018-2023

Others – Market size and forecast 2018-2023

Market opportunity by RoA

PART 07: CUSTOMER LANDSCAPE

PART 08: GEOGRAPHIC LANDSCAPE

Geographic segmentation

Geographic comparison

North America – Market size and forecast 2018-2023

Europe – Market size and forecast 2018-2023

Asia – Market size and forecast 2018-2023

ROW – Market size and forecast 2018-2023

Key leading countries

Market opportunity

PART 09: DECISION FRAMEWORK

PART 10: DRIVERS AND CHALLENGES

Market drivers

Market challenges

PART 11: MARKET TRENDS

Increasing awareness about female infertility

Patient assistance programs

Introduction of biosimilars

PART 12: VENDOR LANDSCAPE

Overview

Landscape disruption

PART 13: VENDOR ANALYSIS

Vendors covered

Vendor classification

Market positioning of vendors

Allergan Plc

Ferring BV

Merck KGaA

Novartis AG

Sanofi

PART 14: APPENDIX

Research methodology

List of abbreviations

Definition of market positioning of vendors

PART 15: EXPLORE TECHNAVIO

Exhibit 01: Global pharmaceuticals market

Exhibit 02: Segments of global pharmaceuticals market

Exhibit 03: Market characteristics

Exhibit 04: Market segments

Exhibit 05: Market definition – Inclusions and exclusions checklist

Exhibit 06: Market size 2018

Exhibit 07: Global market: Size and forecast 2018-2023 ($ millions)

Exhibit 08: Global market: Year-over-year growth 2019-2023 (%)

Exhibit 09: Five forces analysis 2018

Exhibit 10: Five forces analysis 2023

Exhibit 11: Bargaining power of buyers

Exhibit 12: Bargaining power of suppliers

Exhibit 13: Threat of new entrants

Exhibit 14: Threat of substitutes

Exhibit 15: Threat of rivalry

Exhibit 16: Market condition – Five forces 2018

Exhibit 17: RoA – Market share 2018-2023 (%)

Exhibit 18: Comparison by RoA

Exhibit 19: Parenteral – Market size and forecast 2018-2023 ($ millions)

Exhibit 20: Parenteral – Year-over-year growth 2019-2023 (%)

Exhibit 21: Oral – Market size and forecast 2018-2023 ($ millions)

Exhibit 22: Oral – Year-over-year growth 2019-2023 (%)

Exhibit 23: Others – Market size and forecast 2018-2023 ($ millions)

Exhibit 24: Others – Year-over-year growth 2019-2023 (%)

Exhibit 25: Market opportunity by RoA

Exhibit 26: Customer landscape

Exhibit 27: Market share by geography 2018-2023 (%)

Exhibit 28: Geographic comparison

Exhibit 29: North America – Market size and forecast 2018-2023 ($ millions)

Exhibit 30: Number of STD cases in US 2017

Exhibit 31: North America – Year-over-year growth 2019-2023 (%)

Exhibit 32: Top 3 countries in North America

Exhibit 33: Europe – Market size and forecast 2018-2023 ($ millions)

Exhibit 34: Europe – Year-over-year growth 2019-2023 (%)

Exhibit 35: Top 3 countries in Europe

Exhibit 36: Asia – Market size and forecast 2018-2023 ($ millions)

Exhibit 37: Prevalence of infertility in some Indian states

Exhibit 38: Asia – Year-over-year growth 2019-2023 (%)

Exhibit 39: Top 3 countries in Asia

Exhibit 40: ROW – Market size and forecast 2018-2023 ($ millions)

Exhibit 41: ROW – Year-over-year growth 2019-2023 (%)

Exhibit 42: Top 3 countries in ROW

Exhibit 43: Key leading countries

Exhibit 44: Market opportunity

Exhibit 45: Some of the health problems associated with the use of ART

Exhibit 46: Pipeline molecules for treatment of female infertility: Overview

Exhibit 47: Impact of drivers and challenges

Exhibit 48: Cost comparison of follitropin alfa

Exhibit 49: Vendor landscape

Exhibit 50: Landscape disruption

Exhibit 51: Vendors covered

Exhibit 52: Vendor classification

Exhibit 53: Market positioning of vendors

Exhibit 54: Allergan Plc – Vendor overview

Exhibit 55: Allergan Plc – Product segments

Exhibit 56: Allergan Plc – Organizational developments

Exhibit 57: Allergan Plc – Geographic focus

Exhibit 58: Allergan Plc – Segment focus

Exhibit 59: Allergan Plc – Key offerings

Exhibit 60: Allergan Plc – Key customers

Exhibit 61: Ferring BV – Vendor overview

Exhibit 62: Ferring BV – Product segments

Exhibit 63: Ferring BV – Organizational developments

Exhibit 64: Ferring BV – Key offerings

Exhibit 65: Ferring BV – Key customers

Exhibit 66: Merck KGaA – Vendor overview

Exhibit 67: Merck KGaA – Business segments

Exhibit 68: Merck KGaA – Organizational developments

Exhibit 69: Merck KGaA – Geographic focus

Exhibit 70: Merck KGaA – Segment focus

Exhibit 71: Merck KGaA – Key offerings

Exhibit 72: Merck KGaA – Key customers

Exhibit 73: Novartis AG – Vendor overview

Exhibit 74: Novartis AG – Business segments

Exhibit 75: Novartis AG – Organizational developments

Exhibit 76: Novartis AG – Geographic focus

Exhibit 77: Novartis AG – Segment focus

Exhibit 78: Novartis AG – Key offerings

Exhibit 79: Novartis AG – Key customers

Exhibit 80: Sanofi – Vendor overview

Exhibit 81: Sanofi – Business segments

Exhibit 82: Sanofi – Organizational developments

Exhibit 83: Sanofi – Geographic focus

Exhibit 84: Sanofi – Segment focus

Exhibit 85: Sanofi – Key offerings

Exhibit 86: Sanofi – Key customers

Exhibit 87: Validation techniques employed for market sizing

Exhibit 88: Definition of market positioning of vendors